Jan. 19, 2011 - Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable based on obviousness and inequitable conduct.
The district court ruling is available with me. In case of your interest, you can email me at amit@lifelinehisar.com. I will send you the copy of judgement in a summarised manner.
Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®.
Novo Nordisk may appeal this judgement in the federal circuit.
No comments:
Post a Comment